PMID- 31437788
OWN - NLM
STAT- MEDLINE
DCOM- 20200213
LR  - 20201209
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 75
DP  - 2019 Oct
TI  - Umbelliferone reduces the expression of inflammatory chemokines in HaCaT cells 
      and DNCB/DFE-induced atopic dermatitis symptoms in mice.
PG  - 105830
LID - S1567-5769(19)31115-4 [pii]
LID - 10.1016/j.intimp.2019.105830 [doi]
AB  - Umbelliferone (UMB) is a coumarin derivative present in roots and barks of 
      plants, such as Angelica decursiva, Artemisia capillaris, and orange. UMB has 
      been previously reported to exhibit anti-inflammatory, anti-diabetic, and 
      anti-cancer effects. However, the effect of UMB on atopic dermatitis (AD) remains 
      unknown. The purpose of this study was to investigate the anti-atopic effects of 
      UMB on 2,4-dinitrochlorobenzene (DNCB)- and house dust mite extract 
      (Dermatophagoides farinae extract, DFE)-treated mice with AD-like skin lesions 
      and on tumor necrosis factor (TNF)-alpha/interferon (IFN)-gamma-treated HaCaT cells. In 
      DNCB/DFE-treated mice, oral administration of UMB (20 and 40 mg/kg) for 28 days 
      led to a significant decrease in ear thickness, spleen size and weight, serum 
      levels of immunoglobulin E (IgE), IgG1, IgG2a, TNF-alpha, and interleukin 4 (IL-4), 
      and mast cell infiltration; it also led to the suppression of pro-inflammatory 
      cytokines and chemokines. In addition, UMB reduced the secretion of 
      pro-inflammatory cytokines and chemokines in TNF-alpha/IFN-gamma-treated HaCaT cells via 
      regulation of MAPK, IkB-alpha/NF-kappaB, and STAT1 signaling pathways. Taken together, 
      these results indicate that UMB ameliorates AD-associated symptoms and 
      inflammation via regulation of various signaling pathways, suggesting that UMB 
      might be a potential therapeutic agent of AD.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Lim, Ji-Ye
AU  - Lim JY
AD  - Department of Immunology and Institute of Medical Sciences, Medical School, 
      Chonbuk National University, Jeonju, Jeonbuk 54907, Republic of Korea.
FAU - Lee, Ji-Hyun
AU  - Lee JH
AD  - Department of Immunology and Institute of Medical Sciences, Medical School, 
      Chonbuk National University, Jeonju, Jeonbuk 54907, Republic of Korea.
FAU - Lee, Dong-Hyun
AU  - Lee DH
AD  - Department of Obstetrics and Gynecology, Chonbuk National University Medical 
      School, Jeonju, Jeonbuk 54907, Republic of Korea.
FAU - Lee, Jeong-Heon
AU  - Lee JH
AD  - Department of Obstetrics and Gynecology, Chonbuk National University Medical 
      School, Jeonju, Jeonbuk 54907, Republic of Korea. Electronic address: 
      jh.lee@jbnu.ac.kr.
FAU - Kim, Dae-Ki
AU  - Kim DK
AD  - Department of Immunology and Institute of Medical Sciences, Medical School, 
      Chonbuk National University, Jeonju, Jeonbuk 54907, Republic of Korea. Electronic 
      address: daekim@jbnu.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20190819
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antigens, Dermatophagoides)
RN  - 0 (Cytokines)
RN  - 0 (Dinitrochlorobenzene)
RN  - 0 (Umbelliferones)
SB  - IM
MH  - Animals
MH  - Anti-Allergic Agents/pharmacology/*therapeutic use
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Antigens, Dermatophagoides
MH  - Cell Line
MH  - Cytokines/blood/genetics/immunology
MH  - Dermatitis, Atopic/blood/*drug therapy/immunology/pathology
MH  - Dinitrochlorobenzene
MH  - Humans
MH  - Keratinocytes/drug effects
MH  - Male
MH  - Mice, Inbred BALB C
MH  - Skin/drug effects/pathology
MH  - Umbelliferones/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - 2,4-Dinitrochlorobenzene
OT  - Atopic dermatitis
OT  - Dermatophagoides farinae extract
OT  - Umbelliferone, keratinocyte
EDAT- 2019/08/23 06:00
MHDA- 2020/02/14 06:00
CRDT- 2019/08/23 06:00
PHST- 2019/05/23 00:00 [received]
PHST- 2019/08/01 00:00 [revised]
PHST- 2019/08/12 00:00 [accepted]
PHST- 2019/08/23 06:00 [pubmed]
PHST- 2020/02/14 06:00 [medline]
PHST- 2019/08/23 06:00 [entrez]
AID - S1567-5769(19)31115-4 [pii]
AID - 10.1016/j.intimp.2019.105830 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2019 Oct;75:105830. doi: 10.1016/j.intimp.2019.105830. Epub 
      2019 Aug 19.